Shijiazhuang Yiling Pharmaceutical (002603) Fundamentals 2026 — P/E 21.0x, Revenue Analysis | SniperIQ
Shijiazhuang Yiling Pharmaceutical (002603) is a CN-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥28.8B, trading at ¥17.24 on the SHZ. This SniperIQ fundamentals page covers Shijiazhuang Yiling Pharmaceutical's valuation (P/E 21.0x, P/B 2.5x), profitability (net margin 17.3%), revenue (¥7.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shijiazhuang Yiling Pharmaceutical's market cap?
Shijiazhuang Yiling Pharmaceutical (002603) has a market capitalization of approximately ¥28.8B, trading at ¥17.24 on the SHZ. Market cap moves with the live share price.
What is Shijiazhuang Yiling Pharmaceutical's P/E ratio?
Shijiazhuang Yiling Pharmaceutical's trailing twelve-month P/E ratio is 21.0x, with a price-to-book (P/B) of 2.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shijiazhuang Yiling Pharmaceutical?
Shijiazhuang Yiling Pharmaceutical runs a net profit margin of 17.3%, a gross margin of 65.8%, and an operating margin of 23.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shijiazhuang Yiling Pharmaceutical generate?
Shijiazhuang Yiling Pharmaceutical reported revenue of ¥7.8B for fiscal year 2025, with net income of ¥1.3B and earnings per share (EPS) of 0.77. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shijiazhuang Yiling Pharmaceutical pay a dividend?
Shijiazhuang Yiling Pharmaceutical offers a trailing dividend yield of about 4.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shijiazhuang Yiling Pharmaceutical financially healthy?
Shijiazhuang Yiling Pharmaceutical carries a debt-to-equity ratio of 0.00x and a current ratio of 2.50x, with a market beta of 0.47. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shijiazhuang Yiling Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shijiazhuang Yiling Pharmaceutical (002603) the key facts are: market cap ¥28.8B, P/E 21.0x, revenue ¥7.8B, 52-week range 14.22-21.58. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shijiazhuang Yiling Pharmaceutical's full fundamentals live
Get Shijiazhuang Yiling Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.